AstraZeneca's immunotherapy Imfinzi is the first drug therapy to be recommended for routine NHS use as a treatment for ...
MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...
Settle in and check out all 6 Chasing History segments from Golden State's run to the championship in the 2022 NBA Finals. The addition of young NBA prospects, potential contract extensions and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback